



Michael May appointed interim CEO of OmniaBio Inc.

Mitchel Sivilotti recognized for his role in establishing OmniaBio as the commercial development and manufacturing arm of CCRM

Hamilton, ON., September 19, 2025 -- The Board of Directors of OmniaBio Inc., Canada's largest contract development and manufacturing organization (CDMO) for cell and gene therapy (CGT), has accepted the resignation of CEO Mitchel Sivilotti and appointed Michael May as interim CEO.

Mitchel Sivilotti joined CCRM, the parent company of OmniaBio, in 2016 as Chief Operating Officer, where he built the contract services business that would become OmniaBio. In 2022, he moved to OmniaBio as its CEO and led the construction and launch of the Hamilton facility, the hiring of OmniaBio's team, and the integration of existing operations in Toronto. OmniaBio held its grand opening ceremony for the Hamilton facility in October 2024.

The Board is grateful for Mitchel's leadership and the professionalism with which he advanced the mission of OmniaBio.

"Mitchel has made significant contributions in his role at OmniaBio and CCRM, and I appreciate all of his hard work and commitment to turn our vision of OmniaBio into an operational entity that is supporting the needs of cell and gene therapy developers in North America and internationally," says Michael May, Chair, OmniaBio Board of Directors. "We will miss Mitchel's leadership and the experience he brought to the organization."

This commercial-ready facility is enhancing the manufacturing of transformative therapies, further establishing Canada as a hub for innovation, while aiming to increase access and affordability to advanced medical treatments across North America. OmniaBio deploys over a decade of manufacturing and analytical technology expertise, developed through Canadian, U.S. and international partnerships.

Under Michael May's leadership, the team will continue to collaborate with pharmaceutical and biotech companies and academic centres to deliver comprehensive services from process, analytical and associated AI development to commercial manufacturing. Dr. May is

President, CEO, and co-founder of CCRM, where he has led the company since its launch in June 2011.

The Board will commence a formal search for the next President and Chief Executive Officer shortly.

About OmniaBio

OmniaBio Inc. is a global cell and gene therapy CDMO and a subsidiary of CCRM, with over a decade of expertise in regenerative medicine and advanced therapies. OmniaBio specializes in clinical and commercial manufacturing of immune cell-based therapies, induced pluripotent stem cell (iPSC) therapies, CAR-T, and lentiviral vectors, driving advancements in the field and bringing maturity to cell and gene therapy. Please visit us at www.omniabio.com to learn more.

About CCRM

CCRM is a global, public-private partnership headquartered in Canada. It has received funding from the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors, and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a commercial-stage CDMO for manufacturing cell and gene therapies. CCRM is hosted by the University of Toronto. Visit us at ccrm.ca.

-30-

Media contact:

Stacey Johnson
Vice President, Communications and Marketing, CCRM
stacey.johnson@ccrm.ca
1-647-309-1830

For other inquiries, please contact:

Daniel Salvo
Vice President of Marketing and Creative, OmniaBio
daniel.salvo@omniabio.com